Table 1 CSF beta-amyloid peptides (Aß(1-42) and Aß(1-40)), tau and phospho-tau-181 (p-tau-181) protein levels in 39 women in the study group with either mild preeclampsia (PE) or severe PE or HELLP syndrome, compared to 44 healthy controls at delivery.
Mild PE | Severe PE | HELLP syndrome | controls | |
|---|---|---|---|---|
(n = 18) | (n = 13) | (n = 8) | (n = 44) | |
CSF biomarkers | ||||
Aβ(1-42) [pg/ml] | 1,158 ± 444.7 | 1,041 ± 143.3 | 1,071 ± 391.8 | 1,090 ± 166.3 |
Aβ(1-40) [pg/ml] | 7,691 ± 3,837 | 4,836 ± 2,004 | 9,683 ± 5,463 | 6,329 ± 2,114 |
Aβ(1-40)/(1-42) ratio | 6.40 ± 1.80 | 4.71 ± 1.65 | 8.49 ± 2.73 | 5.81 ± 1.97 |
Tau [pg/ml] | 246.7 ± 136.0 | 271.8 ± 127.8 | 240.1 ± 109.7 | 312.9 ± 127.9 |
P-tau-181 [pg/ml] | 42.9 ± 18.8 | 47.7 ± 19.1 | 44.9 ± 18.1 | 50.5 ± 18.1 |
P-tau/tau ratio | 0.19 ± 0.03 | 0.18 ± 0.02 | 0.19 ± 0.01 | 0.16 ± 0.01 |
Serum biomarkers | ||||
sFlt-1 [pg/ml] | 13,819 ± 7690 | 14,369 ± 10,795 | 10,853 ± 7,882 | 3,554 ± 2,185 |
PlGF [pg/ml] | 135.2 ± 143.0 | 105.2 ± 156.2 | 350.8 ± 767.5 | 619.7 ± 398.9 |
sFlt-1/PlGF ratio | 102.2 ± 53.4 | 136.6 ± 69.1 | 30.9 ± 10.3 | 5.7 ± 5.5 |
